PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,725 shares of its common stock and 5,060 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to eight new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
新泽西州沃伦，2024年12月17日 /PRNewswire/ -- PTC Therapeutics, Inc. (纳斯达克: PTCT) 今天宣布，2024年12月13日，公司批准向八名新员工授予非法定股票期权，以购买总计1,725股普通股和5,060个限制性股票单位（"RSUs"），每个单位代表在归属后有权获得一股普通股。这些奖励是根据纳斯达克诱导授予例外，作为新员工就业薪酬的一部分。
The inducement grants were approved by PTC's Compensation Committee on Dec. 13, 2024, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
这些诱导授予于2024年12月13日由PTC的薪酬委员会批准，并作为吸引每位员工接受公司工作的诱导材料，根据纳斯达克上市规则5635(c)(4)进行。
All stock option awards have an exercise price of $46.37 per share, the closing price of PTC's common stock on Dec. 13, 2024, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.
所有股票期权奖励的行使价格为每股46.37美元，为PTC普通股在2024年12月13日授予日期的收盘价格。每个股票期权的有效期为10年，并在四年内归属，其中25%的原始股份在相关员工的新雇佣日期的第一周年时归属，之后每个三个月周期结束时有6.25%的原始股份归属，直到完全归属，前提是员工在相关归属日期继续为公司服务。每个RSU将在四年内归属，25%的原始股份在相关员工的新雇佣日期的每年周年时归属，直到完全归属，前提是员工在相关归属日期继续为公司服务。
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at and follow us on Facebook, Instagram, LinkedIn and X.
关于PTC THERAPEUTICS, INC.
PTC是一家全球生物制药公司，专注于发现、开发和商业化临床差异化的药物，为患有罕见疾病的儿童和成人提供益处。PTC的创新能力体现在识别新疗法和全球商业化产品的基础上，这推动了对强大而多样化的变革性药物管道的投资。PTC的使命是为几乎没有治疗选择的患者提供最佳治疗的获取途径。PTC的策略是利用其强大的科学和临床专业知识以及全球商业基础设施，将疗法带给患者。PTC认为这使它能够为所有利益相关者最大化价值。要了解更多关于PTC的信息，请访问我们并在Facebook、Instagram、LinkedIn和X上关注我们。
For more information please contact:
欲了解更多信息，请联系人：
Investors:
Ellen Cavaleri
+1 (615) 618-8228
[email protected]
投资者：
艾伦·卡瓦莱里
+1 (615) 618-8228
[email protected]
Media:
Jeanine Clemente
+1 (908) 912-9406
[email protected]
媒体：
珍妮娜·克莱门特
+1 (908) 912-9406
[email protected]
SOURCE PTC Therapeutics, Inc.
来源 PTC Therapeutics, Inc.
